Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis

MalaCards integrated aliases for Hepatitis:

Name: Hepatitis 12 74 29 54 6 42 43 15 37 71
Chronic Persistent Hepatitis 12 54 71
Chronic Hepatitis 12 15 17
Hepatitis, Chronic 43 71
Acute Hepatitis 12 71
Acute and Subacute Liver Necrosis 12
Acute/subac. Necrosis of Liver 12
Hepatitis Chronic 54
Hepatitis, Animal 71
Animal Hepatitis 12
Hepatitis a 71


External Ids:

Disease Ontology 12 DOID:2237
NCIt 49 C82978
SNOMED-CT 67 41889008 76783007
ICD10 32 K73 K73.0 K73.9
UMLS 71 C0001308 C0019158 C0019159 more

Summaries for Hepatitis

MedlinePlus : 42 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. Viruses cause most cases of hepatitis. The type of hepatitis is named for the virus that causes it; for example, hepatitis A, hepatitis B or hepatitis C. Drug or alcohol use can also cause hepatitis. In other cases, your body mistakenly attacks healthy cells in the liver. Some people who have hepatitis have no symptoms. Others may have Loss of appetite Nausea and vomiting Diarrhea Dark-colored urine and pale bowel movements Stomach pain Jaundice, yellowing of skin and eyes Some forms of hepatitis are mild, and others can be serious. Some can lead to scarring, called cirrhosis, or to liver cancer. Sometimes hepatitis goes away by itself. If it does not, it can be treated with drugs. Sometimes hepatitis lasts a lifetime. Vaccines can help prevent some viral forms.

MalaCards based summary : Hepatitis, also known as chronic persistent hepatitis, is related to hepatitis d and viral hepatitis, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Hepatitis is GPT (Glutamic--Pyruvic Transaminase), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Vitamin digestion and absorption. The drugs glycyrrhizin and Acarbose have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Hepatitis is inflammation of the liver tissue. Some people with hepatitis have no symptoms, whereas... more...

Related Diseases for Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3444)
# Related Disease Score Top Affiliating Genes
1 hepatitis d 35.1 IFNA2 IFNA1 GPT
2 viral hepatitis 34.9 SLC17A5 SEPSECS KRT8 IFNA2 IFNA1 GPT
3 hepatitis a 34.9 SEPSECS IFNA2 IFNA1 HAVCR2 HAVCR1 GPT
4 hepatitis c 34.9 SCARB1 KRT8 IFNAR2 IFNA2 IFNA1 GPT
5 autoimmune hepatitis 34.8 SLC17A5 SEPSECS KRT8 IFNA1 GPT ASGR2
6 hepatitis c virus 34.7 SCARB1 PSMA7 KRT8 HAVCR2 GPT CLDN6
7 hepatitis b 34.6 SLC17A5 SLC10A1 RSF1 PSMA7 NR5A2 LAMTOR5
8 liver disease 34.1 SLC17A5 SLC10A1 SEPSECS KRT8 IFNA1 GPT
9 fatty liver disease, nonalcoholic 1 34.0 SLC17A5 GPT
10 liver cirrhosis 33.6 SLC17A5 KRT8 IFNA1 GPT
11 infantile liver failure syndrome 1 33.3 SLC17A5 GPT
12 cryoglobulinemia 32.2 IFNA2 IFNA1 GPT
13 non-alcoholic steatohepatitis 32.1 SLC17A5 GPT
14 cryoglobulinemia, familial mixed 32.1 IFNA2 IFNA1
15 cholangitis 32.1 SLC17A5 GPT CLDN1
16 viral infectious disease 31.7 SLC17A5 IFNAR2 IFNA2 IFNA1 GPT
17 primary biliary cirrhosis 31.6 SLC17A5 SLC10A1 SEPSECS GPT
18 cholangitis, primary sclerosing 31.6 SLC10A1 SEPSECS GPT
19 splenomegaly 31.3 IFNA2 IFNA1
20 scrub typhus 30.8 SLC17A5 HAVCR1 GPT
21 suppurative cholangitis 30.7 SEPSECS GPT
22 kwashiorkor 30.7 SLC17A5 GPT
23 pyridoxine deficiency anemia 30.4 SLC17A5 GPT
24 parenteral nutrition-associated cholestasis 30.4 SLC17A5 GPT
25 paraquat poisoning 30.3 SLC17A5 GPT
26 discoid lupus erythematosus 30.3 IFNA2 IFNA1
27 pyuria 30.1 HAVCR1 GPT
28 methotrexate toxicity 30.1 SLC17A5 GPT
29 analbuminemia 30.0 SLC17A5 GPT
30 hepatic veno-occlusive disease 12.7
31 hepatic venoocclusive disease with immunodeficiency 12.7
32 hepatic lipase deficiency 12.7
33 hepatic encephalopathy 12.7
34 alcoholic hepatitis 12.7
35 hepatitis e 12.6
36 congenital hepatic fibrosis 12.6
37 hepatitis, fulminant viral 12.5
38 hepatic adenomas, familial 12.5
39 non-a-e hepatitis 12.5
40 renal-hepatic-pancreatic dysplasia 12.5
41 renal-hepatic-pancreatic dysplasia 2 12.5
42 drug-induced hepatitis 12.5
43 hepatic fibrosis, severe due to schistosoma mansoni infection 12.5
44 porphyria, acute hepatic 12.4
45 renal-hepatic-pancreatic dysplasia 1 12.4
46 hepatic flexure cancer 12.4
47 hepatic coma 12.4
48 epstein-barr virus hepatitis 12.4
49 acute liver failure 12.4
50 granulomatous hepatitis 12.3

Comorbidity relations with Hepatitis via Phenotypic Disease Network (PDN): (show all 14)

Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Cholangitis Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hepatic Encephalopathy
Hypothyroidism Mitral Valve Disease
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatitis:

Diseases related to Hepatitis

Symptoms & Phenotypes for Hepatitis

UMLS symptoms related to Hepatitis:

nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, hepatosplenomegaly, lameness, animal, icterus, dyspepsia, heartburn, gastrointestinal gas, hepatocellular jaundice

GenomeRNAi Phenotypes related to Hepatitis according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 10 PSMA7
2 Decreased viability GR00381-A-1 10 PSMA7
3 Decreased viability GR00402-S-2 10 ASGR2 CCDC85B CLDN1 CLDN6 GPT HAVCR1
4 no effect GR00402-S-1 9.62 ASGR2 CCDC85B CLDN1 CLDN6 GPT HAVCR1

Drugs & Therapeutics for Hepatitis

Drugs for Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 870)
# Name Status Phase Clinical Trials Cas Number PubChem Id
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
Insulin glulisine Approved Phase 4 207748-29-6
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
Gliclazide Approved Phase 4 21187-98-4 3475
Glyburide Approved Phase 4 10238-21-8 3488
Glimepiride Approved Phase 4 93479-97-1 3476
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
Promethazine Approved, Investigational Phase 4 60-87-7 4927
Losartan Approved Phase 4 114798-26-4 3961
Simethicone Approved Phase 4 8050-81-5
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Racepinephrine Approved Phase 4 329-65-7 838
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Colchicine Approved Phase 4 64-86-8 6167 2833
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
27 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
Zidovudine Approved Phase 4 30516-87-1 35370
Didanosine Approved Phase 4 69655-05-6 50599
Citalopram Approved Phase 4 59729-33-8 2771
Meperidine Approved Phase 4 57-42-1 4058
Infliximab Approved Phase 4 170277-31-3
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
Fosamprenavir Approved Phase 4 226700-79-4 131536
Halofantrine Approved Phase 4 69756-53-2 37393
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
Polyestradiol phosphate Approved Phase 4 28014-46-2
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Nelfinavir Approved Phase 4 159989-64-7 64143
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Metronidazole Approved Phase 4 443-48-1 4173
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049

Interventional clinical trials:

(show top 50) (show all 5028)
# Name Status NCT ID Phase Drugs
1 Study to Identify Eligible Subjects Using Response Guided Therapy-Stopping Rule for Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults. Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
2 PhaseIVstudy to Evaluate the Non-inferiority of Cavir®Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude® Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude® Tab Unknown status NCT02523547 Phase 4 Cavir;Baraclude
3 Efficacy of Long-term Telbivudine Treatment on Histological Improvements in Patients With Chronic Hepatitis B (EFFORT Further Extension Study) Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
5 A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin Unknown status NCT01439776 Phase 4
6 A Multi-center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Generic Entecavir Monotherapy or in Combination With Adefovir for Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
7 A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
8 Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B Unknown status NCT01380951 Phase 4 telbivudine
9 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
10 A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Therapy for Patients Previously Treated in Dragon Study Unknown status NCT01829685 Phase 4 Entecavir, Adefovir
11 The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
12 Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
13 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
14 Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
15 The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
16 Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
17 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
18 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
19 A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection Unknown status NCT00939068 Phase 4 Telbivudine
20 A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy Unknown status NCT02594293 Phase 4 PegIFN alfa-2a
21 Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
22 A Prospective, Open-label, Multicenter Study of Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
23 A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
24 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
25 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
26 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
27 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
28 HBsAg Clearance of Peginterferon Treatment in Patients Who Had Chronic Hepatitis B and Were on the Treatment of Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
29 The Changes of Natural Killer Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B. Unknown status NCT03208998 Phase 4 Peginterferon Alfa-2a
30 An Open-Label Study to Evaluate Long-Term Outcomes With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Fertile Women With Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection Unknown status NCT02950870 Phase 4 Ombitasvir-Paritaprevir-Ritonavir;Dasabuvir;Ribavirin
31 A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
32 The Changes of CD8+T Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B Unknown status NCT03209037 Phase 4 Peginterferon Alfa-2a
33 The Changes of CD4+T Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B Unknown status NCT03209011 Phase 4 Peginterferon Alfa-2a
34 Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment Unknown status NCT01491295 Phase 4 Tenofovir disoproxil fumarate;Lamivudine plus adefovir
35 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
36 Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase Unknown status NCT01833611 Phase 4 Entecavir;placebo
37 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
38 A Randomized, Prospective, Multicenter, Open-label Study to Evaluate the Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir in HBeAg-positive Chronic Hepatitis B Patients Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
39 Randomized Study Comparing Nucleoside Analogues Plus Tenofovir and Nucleoside Analogues Plus Adefovir in Chronic Hepatitis B Patients With Suboptimal Response to Adefovir-based Combination Therapy Due to Nucleoside Analogues Resistance Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
40 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
41 A Randomized, Double Blind Controlled Trial to Evaluate the Therapeutic Effect of Telbivudine With or Without Prednisolone Priming in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4 Prednisolone;Placebo priming
42 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
43 Efficacies of Entecavir Add on Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 6 Months Treatment of Peginterferon Alpha 2a Unknown status NCT02368288 Phase 4 entecavir
44 A Randomized, Open-label, Multi-center Clinical Trial to Evaluate Addition of Peginterferon Alfa-2a to CHB Patients Treated With NAs and Achieved HBV DNA<15 IU/ml、HBeAg<100 PEIU/ml、HBsAg Positive and HBsAg<1500 IU/ml. Unknown status NCT02894918 Phase 4 Peginterferon alfa-2a
45 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection. Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
46 A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
47 An Open-label, Multi-center, Randomized Study Comparing the Effects of Oral Hypoglycemic Agents on Viral Kinetics of Chronic Hepatitis C Patients Receiving Pegylated Interferon Alfa 2b Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
48 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
49 Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
50 An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin

Search NIH Clinical Center for Hepatitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Astragalus preparation
Milk thistle extract

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis:
Promethera HepaStem, human adult liver progenitor cells for liver diseases
Embryonic/Adult Cultured Cells Related to Hepatitis:
Adult liver progenitor cells PMIDs: 22525602 23211283 24142276 22900053 19091822

Cochrane evidence based reviews: hepatitis

Genetic Tests for Hepatitis

Genetic tests related to Hepatitis:

# Genetic test Affiliating Genes
1 Hepatitis 29

Anatomical Context for Hepatitis

MalaCards organs/tissues related to Hepatitis:

Liver, Testes, Kidney, T Cells, Bone, B Cells, Heart

Publications for Hepatitis

Articles related to Hepatitis:

(show top 50) (show all 31675)
# Title Authors PMID Year
The genetic variants in calcium signaling related genes influence anti-tuberculosis drug induced liver injury: A prospective study. 42
31689868 2019
A case report of glecaprevir/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis. 42
31574875 2019
Roles of Hepatic Drug Transporters in Drug Disposition and Liver Toxicity. 42
31571168 2019
Does hepatitis C virus affect the reactivation of hepatitis B virus following renal transplantation? 54 61
16390851 2006
Role of hepatitis C virus in cardiomyopathies. 54 61
16329660 2006
Autoimmune hepatitis triggered by acute hepatitis A. 54 61
16273628 2005
Hepatitis C virus core protein and hepatitis activity are associated through transactivation of interleukin-8. 54 61
15962221 2005
Prolonged acute hepatitis A mimicking autoimmune hepatitis. 54 61
15968741 2005
Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. 54 61
15756144 2005
Autoimmune hepatitis: evolving concepts. 54 61
15110233 2004
Coinfection of chronic hepatitis B and fasciolosis. 54 61
15007744 2004
Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus. 54 61
15564749 2004
[HFE gene mutations, hepatic iron content, and histological severity in hepatitis C virus-induced chronic hepatitis]. 54 61
14972004 2003
Does previous hepatitis A infection affect the clinicopathological status of chronic hepatitis C? 54 61
12845983 2003
Acute hepatitis associated with Barakol. 54 61
12930029 2003
[Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C]. 54 61
12501575 2002
Polyphyletic strains of hepatitis E virus are responsible for sporadic cases of acute hepatitis in Japan. 54 61
12202555 2002
Hepatitis B surface antigenemia in chronic hemodialysis patients: effect of hepatitis B immunization. 54 61
11808938 2002
Therapeutic vaccination in chronic hepatitis B. 54 61
11895556 2002
Development of multicentric hepatocellular carcinoma after completion of interferon therapy. 54 61
12203085 2002
Increased soluble P-selectin levels in hepatitis C virus-related chronic hepatitis: correlation with viral load. 54 61
11523696 2001
Combining hepatitis A and B vaccination in children and adolescents. 54 61
11257370 2001
Treatment options in patients with chronic hepatitis C. 54 61
11059126 2000
Prostate-specific antigen in acute hepatitis and hepatocellular carcinoma. 54 61
10544299 1999
Correlation of viral RNA, alanine aminotransferase, and histopathology in hepatitis C virus-associated hepatitis. 54 61
10553026 1999
Lamivudine for chronic delta hepatitis. 54 61
10421666 1999
Interferon-alpha in chronic hepatitis C infection in dialysis patients. 54 61
10401016 1999
The mouse interferon-gamma transgene chronic hepatitis model (Review). 54 61
10202184 1999
Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. 54 61
10363572 1999
Association of hepatitis viruses with hepatocellular carcinoma in Thailand. 54 61
10213123 1999
[Serial hepatic and splenic volumetry in acute severe hepatitis]. 54 61
10087886 1999
Hepatitis virus infection in haemodialysis patients from Moldavia. 54 61
10052474 1999
[Drug-induced hepatitis]. 54 61
10647202 1999
Autoantibody to the liver arginase present in sera of patients with autoimmune hepatitis and chronic hepatitis. 54 61
10520898 1999
De novo hepatitis C in children after liver transplantation. 54 61
9721798 1998
Treatment of fibrosing cholestatic hepatitis with lamivudine. 54 61
9649474 1998
[Cholestatic hepatitis associated with piroxicam use. Case report]. 54 61
9731437 1998
Phylogenetic analysis of hepatitis GB virus type C/hepatitis G virus in Spanish patients with chronic hepatitis B or C virus infection. 54 61
10325532 1998
Prediction of effect of interferon on chronic hepatitis C. 54 61
9398805 1997
Current therapeutic trends in therapy for chronic viral hepatitis. 54 61
9407357 1997
Efficacy of interferons in treating children with chronic hepatitis C. 54 61
9296534 1997
Plasma collagen-binding vitronectin activated by heparin and dextran sulfate in chronic liver disease. 54 61
9387191 1997
Granulomatous hepatitis in a patient with chronic hepatitis C treated with interferon-alpha. 54 61
9246044 1997
Anti-p53 autoantibodies in hepatitis C virus-infected patients. 54 61
9329606 1997
Visual and auditory evoked responses in acute severe hepatitis. 54 61
9257251 1997
Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. 54 61
9210606 1997
Expression of IFN-inducible protein-10 in chronic hepatitis. 54 61
9164978 1997
[Interferon treatment for hepatitis G virus infection in patients with chronic hepatitis C]. 54 61
9086771 1997
Changes in results of Gallium-67-citrate scanning after interferon therapy for chronic hepatitis C. 54 61
9025739 1997
Nucleotide sequence diversity of hypervariable region 1 of hepatitis C virus in Japanese hemophiliacs with chronic hepatitis C and patients with chronic posttransfusion hepatitis C. 54 61
8695870 1996

Variations for Hepatitis

ClinVar genetic disease variations for Hepatitis:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MT-TL1 NC_012920.1:m.3275C>TSNV Benign 370045 rs1057516057 MT:3275-3275 MT:3275-3275

Copy number variations for Hepatitis from CNVD:

# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 226111 7 55054218 55242525 Amplification EGFR Hepatitis

Expression for Hepatitis

Search GEO for disease gene expression data for Hepatitis.

Pathways for Hepatitis

GO Terms for Hepatitis

Cellular components related to Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apicolateral plasma membrane GO:0016327 8.96